Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

480 RIFAMPIN
Other
Anaphylactoid reactions/Anaphylaxis
(1999): Garcia F+, Allergy 54, 527 (to topical)
(1999): Magnan A+, J Allergy Clin Immunol 103, 954
(1998): Erel F+, Ann Allergy Asthma Immunol 81, 257
(1995): Cardot E+, J Allergy Clin Immunol 95, 1
(1989): Piazza I, Allergologia 12, 96 (suppl)
(1989): Wurtz RM+, Lancet 1, 955 (in AIDS patients)
Death
(2003): Castro KG+, Chest 123(3), 967 (with pyrazinamide)
(2002): Medinger A, Chest 121(5), 1710 (with pyrazinamide)
(2002): No authors, JAMA 288(23), 2967 (with pyrazinamide)
(2002): No authors, MMWR Morb Mortal 51(44), 998 (with
pyrazinamide)
(2001): No authors, CanCommunDisRep27(13), 114 (with
pyrazinamide)
(2001): No authors, JAMA 286(12), 1445 (with pyrazinamide)
(2001): No authors, MMWR Morb Mortal Wkly Rep 50(34), 733
(with pyrazinamide)
Hepatotoxicity
(2006): Cook PP+, Clin Infect Dis 43(3), 271 (6%) (with
pyrazinamide)
(1999): Gallieni M+, Int J Artif Organs 22(7), 477
Hypersensitivity
(2006): Buergin S+, Int Arch Allergy Immunol 140(1), 20
Injection-site erythema
(1988): Fan-Havard P+, Clin Pharm 7, 616
Myalgia/Myositis/Myopathy/Myotoxicity
Nephrotoxicity
(2006): Jover-Saenz A+, Enferm Infecc Microbiol Clin 24(1), 64
(1999): Gallieni M+, Int J Artif Organs 22(7), 477
Porphyria
(1985): Holdiness MR, Int J Dermatol 24, 280
(1982): Igual JP+, Presse Med (French) 11, 2846
Porphyria cutanea tarda
(1980): Millar JW, Br J Dis Chest 74, 405
Serum sickness
(1994): Parra FM+, Ann Allergy 73, 123
RIFAPENTINE
Trade name: Priftin (Sanofi-Aventis)
Indications: Tuberculosis
Category: Antibiotic, rifamycin
Half-life: 14–17 hours
Clinically important, potentially hazardous interactions
with: amiodarone, anisindione, anticoagulants, corticosteroids,
cyclosporine, dicumarol, indinavir, ritonavir, solifenacin,
tacrolimus, warfarin
Skin
Acne (1–10%)
Peripheral edema (